Claims
- 1. A topical pharmaceutical composition for lightening skin or reducing the pigmentation of skin in a human, comprising an amount of a compound of formula I
- 2. The composition of claim 1, further comprising a sunscreen.
- 3. The composition of claim 1, further comprising resveratrol or another active agent that is an anti-oxidant.
- 4. The composition of claim 1, further comprising retinoic acid, a derivative of retinoic acid, or any compound that interacts with retinoic acid receptors and accelerates or enhances the composition's ability to reduce skin melanin and skin bleaching action.
- 5. The composition of claim 1, further comprising glycolic acid, trichloroacetic acid or another skin peeling agent.
- 6. The composition of claim 1, which is in the form of a water-alcohol solution, an oil-in-water emulsion, a water-in-oil emulsion, an emulsified gel, or a two-phase system.
- 7. The composition of claim 1, which is in the form of a lotion, cream, milk, gel, jelly, paste, ointment, salve, mask, microspheres, nanospheres, or a vesicular dispersion.
- 8. The composition of claim 1, wherein the skin-lightening or pigmentation-reducing amount of the compound of formula I or pharmaceutically acceptable salt thereof is an amount effective to inhibit tyrosinase.
- 9. A method of lightening skin or reducing the pigmentation of skin in a human, comprising administering to said human an amount of a compound of formula I
- 10. The method of claim 9, in which the compound of formula I or the pharmaceutically acceptable salt thereof is formulated in a water-alcohol solution, an oil-in-water emulsion, a water-in-oil emulsion, an emulsified gel, or a two-phase system.
- 11. The method of claim 9, in which the compound of formula I or the pharmaceutically acceptable salt thereof is formulated in a lotion, cream, milk, gel, jelly, paste, ointment, salve, mask, microspheres, nanospheres, or a vesicular dispersion.
- 12. The method of claim 9, wherein the skin-lightening or pigmentation-reducing amount of the compound of formula I or pharmaceutically acceptable salt thereof is an amount effective to inhibit tyrosinase.
- 13. A method of inhibiting tyrosinase in a human, comprising administering to said human a tyrosinase-inhibiting effective amount of a compound of formula I
- 14. The method of claim 13, in which the compound of formula I or the pharmaceutically acceptable salt thereof is formulated in a water-alcohol solution, an oil-in-water emulsion, a water-in-oil emulsion, an emulsified gel, or a two-phase system.
- 15. The method of claim 13, in which the compound of formula I or the pharmaceutically acceptable salt thereof is formulated in a lotion, cream, milk, gel, jelly, paste, ointment, salve, mask, microspheres, nanospheres, or a vesicular dispersion.
- 16. A method of treating an inflammatory disorder or dandruff in a human, comprising administering to said human an amount of a compound of formula I
- 17. The method of claim 16, wherein the inflammatory disorder is psoriasis, dermatitis or acne.
Parent Case Info
[0001] This application is a continuation-in-part of application Ser. No. 09/525,643, filed Mar. 15, 2000, which claims priority from U.S. provisional application No. 60/125,553, filed Mar. 22, 1999, which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60125553 |
Mar 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09525643 |
Mar 2000 |
US |
Child |
10061040 |
Jan 2002 |
US |